Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy.
Perkins BA, Soleymanlou N, Rosenstock J, Skyler JS, Laffel LM, Liesenfeld KH, Neubacher D, Riggs MM, Johnston CK, Eudy-Byrne RJ, Elmokadem A, George JT, Marquard J, Nock V. Perkins BA, et al. Among authors: soleymanlou n. Diabetes Obes Metab. 2020 Mar;22(3):427-433. doi: 10.1111/dom.13945. Epub 2020 Jan 21. Diabetes Obes Metab. 2020. PMID: 31858718 Free PMC article.
Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1).
Famulla S, Pieber TR, Eilbracht J, Neubacher D, Soleymanlou N, Woerle HJ, Broedl UC, Kaspers S. Famulla S, et al. Among authors: soleymanlou n. Diabetes Technol Ther. 2017 Jan;19(1):49-60. doi: 10.1089/dia.2016.0261. Epub 2016 Dec 8. Diabetes Technol Ther. 2017. PMID: 27929674 Clinical Trial.
Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
Shimada A, Hanafusa T, Yasui A, Lee G, Taneda Y, Sarashina A, Shiki K, George J, Soleymanlou N, Marquard J. Shimada A, et al. Among authors: soleymanlou n. Diabetes Obes Metab. 2018 Sep;20(9):2190-2199. doi: 10.1111/dom.13351. Epub 2018 Jun 5. Diabetes Obes Metab. 2018. PMID: 29766633 Free PMC article. Clinical Trial.
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, Zinman B, Skyler JS, George J, Soleymanlou N, Perkins BA. Rosenstock J, et al. Among authors: soleymanlou n. Diabetes Care. 2018 Dec;41(12):2560-2569. doi: 10.2337/dc18-1749. Epub 2018 Oct 4. Diabetes Care. 2018. PMID: 30287422 Clinical Trial.
Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes.
Perkins BA, Rosenstock J, Skyler JS, Laffel LM, Cherney DZ, Mathieu C, Pang C, Wood R, Kinduryte O, George JT, Marquard J, Soleymanlou N. Perkins BA, et al. Among authors: soleymanlou n. Diabetes Care. 2019 Sep;42(9):1716-1723. doi: 10.2337/dc19-0548. Epub 2019 Jun 8. Diabetes Care. 2019. PMID: 31177179 Free PMC article.
Kidney Effects of Empagliflozin in People with Type 1 Diabetes.
Cherney DZI, Bjornstad P, Perkins BA, Rosenstock J, Neubacher D, Marquard J, Soleymanlou N. Cherney DZI, et al. Among authors: soleymanlou n. Clin J Am Soc Nephrol. 2021 Nov;16(11):1715-1719. doi: 10.2215/CJN.07700621. Epub 2021 Sep 17. Clin J Am Soc Nephrol. 2021. PMID: 34535454 Free PMC article. No abstract available.
28 results